Comparison of roxithromycin with co-amoxiclav in patients with sinusitis.
In an open, randomized study of 60 patients with acute or recurrent sinusitis, the bacteriological and clinical efficacy of roxithromycin 150 mg bd were compared with those of po co-amoxiclav (625 mg) tds. Of 52 patients who underwent sinus puncture for isolation of causative organisms, 48 had pathogens sensitive to both antibiotics. Satisfactory clinical response was obtained in 93.1% (27/29) evaluable patients receiving roxithromycin and 88.8% (24/27) receiving co-amoxiclav. Tolerability was significantly better in the roxithromycin group, with 1/29 (3.4%) patients in this group experiencing gastrointestinal side-effects, compared with 7/27 (25.9%) patients in the co-amoxiclav group (P < 0.05). Although the study had limited power to detect differences, roxithromycin demonstrated clinical, bacteriological and overall efficacy similar to that of co-amoxiclav, but with better tolerability. Roxithromycin thus appears to be an effective and well-tolerated drug for the treatment of acute and recurrent sinusitis.
Chatzimanolis
E
E
Erythros Hospital, Athens, Greece.
Marsan
N
N
Lefatzis
D
D
Pavlopoulos
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001442:Bacteroides Infections / Q000188:drug therapy; D001441:Bacteroides fragilis; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy; D006193:Haemophilus influenzae; D006801:Humans; D008297:Male; D008875:Middle Aged; D001936:Moraxella catarrhalis; D016870:Neisseriaceae Infections / Q000188:drug therapy; D011008:Pneumococcal Infections / Q000188:drug therapy; D015575:Roxithromycin / Q000009:adverse effects / Q000627:therapeutic use*; D012852:Sinusitis / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013296:Streptococcus pneumoniae
D000900:Anti-Bacterial Agents; D015575:Roxithromycin; D019980:Amoxicillin-Potassium Clavulanate Combination